Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › raltegravir

raltegravir

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of raltegravir

70 trials tracked of raltegravir: 35 in phase 3 or 4 and 8 with published results. The most-cited published study has 56 citations.

70Trials tracked
35Phase 3 & 4
0Recruiting
8With published results
Phase distribution
Phase 4 20 Phase 3 15 Phase 2 7 Phase 1 6 Other / NA 22
  1. Phase 4 A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure Completed · 56 cited
  2. Phase 4 Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Completed · 46 cited
  3. Phase 4 Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds Completed · 42 cited
  4. Phase 4 Effects of Raltegravir Based Regimen on Platelet Reactivity, Platelet-monocyte Aggregation and Immune Activation Completed · 36 cited
  5. Phase 3 Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292) Completed · 35 cited
  6. Phase 4 The Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age Completed · 12 cited
Show 44 more trials
  1. Phase 4 Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen Completed · 11 cited
  2. Phase 4 Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir Completed · 9 cited
  3. Phase 4 Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients Completed
  4. Phase 4 Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851) Completed
  5. Phase 4 Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection Completed
  6. Phase 4 A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen Completed
  7. Phase 4 Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients Completed
  8. Phase 4 A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects Completed
  9. Phase 4 Raltegravir Intensification in HIV-infected Patients Completed
  10. Phase 4 Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response Completed
  11. Phase 4 Bone and Body Comp: A Sub Study of the SECOND-LINE Study Completed
  12. Phase 4 Switch From Tenofovir to Raltegravir for Low Bone Mineral Density Completed
  13. Phase 4 Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients Completed
  14. Phase 4 Effect of Raltegravir on Endothelial Function in HIV-Infected Patients Completed
  15. Phase 4 Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP) Completed
  16. Phase 3 Effects of Intensive cART During Acute/Early HIV Infection Completed
  17. Phase 3 Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY Completed
  18. Phase 3 Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM Completed
  19. Phase 3 Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects Completed
  20. Phase 3 Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir Completed
  21. Phase 3 A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2) Completed
  22. Phase 3 Optimizing Treatment for Treatment-Experienced, HIV-Infected People Completed
  23. Phase 3 A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults Completed
  24. Phase 3 A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Completed
  25. Phase 3 Comparative Study of Three NNRTI-Sparing HAART Regimens Completed
  26. Phase 3 Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid Completed
  27. Phase 3 Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy Completed
  28. Phase 3 A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019) Completed
  29. Phase 3 Study of Options for Second-Line Effective Combination Therapy (SELECT) Completed
  30. Phase 2 EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma Completed
  31. Phase 2 Raltegravir Therapy for Women With HIV and Fat Accumulation Completed
  32. Phase 2 Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir Completed
  33. Phase 2 Research In Viral Eradication of HIV Reservoirs Completed
  34. Phase 2 Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults Completed
  35. Phase 2 Safety, Tolerance and Pharmacokinetics of Raltegravir-Containing Antiretroviral Therapy in Infants, Children Infected With HIV and TB Completed
  36. Phase 2 Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis Completed
  37. Phase 1 The Raltegravir and Ribavirin Pharmacokinetics (PK) Study Completed
  38. Phase 1 A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs Completed
  39. Phase 1 A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247) Completed
  40. Phase 1 Investigation of Faldaprevir Effect on Pharmacokinetics of Raltegravir Completed
  41. Phase 1 A Two Way Cross Over Pharmacokinetic Interaction Study Between Raltegravir and Amlodipine in Healthy Volunteers Completed
  42. Phase 1 Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection Completed
  43. N/A Comparing Raltegravir Genital Tract Distribution in HIV-infected Men and Women Completed
  44. N/A Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut Completed

Showing the 50 most-cited and recently-updated of 70 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Phase 4 trial compares LPV/r plus raltegravir versus LPV/r plus N(t)RTIs for HIV after first-line failure
Allergy & Immunology Phase IV
Phase 4 trial compares LPV/r plus raltegravir versus LPV/r plus N(t)RTIs for HIV after first-line failure Study compares two HIV treatment strategies after first-line therapy fails
A phase 4 randomized controlled trial enrolled 558 HIV-infected subjects who had virologically failed first-line NNRTI-based therapy.
A completed Phase 4 trial compared two HIV treatment strategies after first-line therapy fails, but results for viral suppression and safety…
CT.gov Mar 30, 2026